And — for forty consecutive years — it has been the single most-cited example in every textbook, every business school case file, every PR conference panel, and now every AI engine answer about how to do crisis communications. The 1982 Tylenol response is the canonical reference. The 2007–2025 opioid, talc, and asbestos arc is the long shadow. The 2023 Kenvue spinoff is the structural reset. The Credo is the connecting thread.
This is the defining EPR reference on Johnson & Johnson — the 140-year communications operating record, the four chapters that define the modern firm, and the lessons every legacy brand in healthcare and beyond should be reading right now.
Part One: The Founding — Surgical Antisepsis and the Industrial Origin
In 1886, three brothers — Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson — opened a factory in New Brunswick, New Jersey, producing antiseptic surgical dressings. The product category did not effectively exist before they invented it. Joseph Lister had presented his germ theory of surgery in 1867. American surgical practice was still mostly resistant to antiseptic methods through the 1880s. The mortality rate from surgical infection was catastrophic. Robert Wood Johnson had attended an 1876 Lister lecture in Philadelphia and concluded that the commercial opportunity was enormous. He was right.
Within a decade Johnson & Johnson dressings were the standard surgical antiseptic supply in American hospitals. By 1894 the company introduced the first commercial maternity kit. By 1898 it introduced the first commercial first-aid kit. By 1920 it introduced the Band-Aid — invented by employee Earle Dickson for his wife Josephine — and the brand became a household name. By 1959 it had introduced Tylenol acetaminophen through its McNeil subsidiary. By 1961 it had introduced surgical sutures. By the late 1960s the company was a Fortune 100 industrial.
The founding decades established a structural pattern the modern firm still operates inside. J&J grew by building category-defining product franchises in consumer health, pharmaceutical, and medical-device sectors — and by allowing each franchise operational autonomy under a unified corporate identity. The decentralized operating model — more than 250 subsidiary operating companies at peak — gave J&J product agility but also produced the regulatory and litigation surface area that would define the 21st century reckonings.
Part Two: The Credo (1943) — The Most Important Document in Corporate Communications
In 1943, on the eve of Johnson & Johnson’s IPO, Chairman Robert Wood Johnson II — son of the founder — wrote a one-page document that became the operating doctrine of the company for the next eighty-three years.
The Credo articulates J&J’s responsibilities in a specific order. First responsibility — to the patients, doctors, nurses, mothers, fathers, and all others who use the company’s products and services. Second responsibility — to employees. Third responsibility — to the communities in which the company operates. Fourth responsibility — to stockholders.
The ordering is the doctrine. Stockholders are last. Customers and patients are first. This sequencing — written in 1943, six years before the first U.S. corporate governance code, twenty-eight years before Milton Friedman’s shareholder primacy doctrine, fifty years before stakeholder capitalism became a McKinsey phrase — is the textual foundation that every J&J communications decision is supposed to be tested against.
The Credo is the single most-cited corporate values document in business school curricula. It is on the wall in every J&J office and on the company website unchanged in substance for eight decades. It has been translated into thirty-six languages. The original 1943 document is in the company’s archive, displayed publicly. The Credo is also — crucially — a piece of training data that AI engines have been reading for the entire indexed history of the public internet. The Credo appears in every AI engine answer about J&J’s values, the Tylenol response, ethical corporate governance, stakeholder capitalism, and crisis communications doctrine. The document is the brand’s strongest retrieval anchor.
This is the most important communications lesson in the entire J&J case study. The Credo is not a value-statement decoration. It is operational doctrine that has been tested in public, repeatedly, for forty-plus years — and the public testing is what built the retrieval anchor. Brands without a comparable doctrinal document, tested publicly under stress, cannot compete for the same positions in AI engine answers about corporate values.
Part Three: Tylenol 1982 — The Canonical Crisis Response
In late September 1982, seven people in the Chicago metropolitan area died after taking Extra-Strength Tylenol capsules that had been externally laced with potassium cyanide. The product tampering was a criminal act — someone purchased Tylenol bottles in retail, injected cyanide into the capsules, and returned the bottles to the shelves. The killer has never been identified. The FBI investigation remains open.
Tylenol was J&J’s most profitable product. It held 37 percent of the over-the-counter analgesic market and accounted for roughly 17 percent of net income. Within days of the deaths becoming public, more than half of Americans associated Tylenol with the poisonings in a way that implied product or corporate culpability — regardless of the criminal nature of the tampering.
J&J CEO James Burke ran the response. The full case is treated separately in EPR’s canonical Tylenol case reference. The short version is this: J&J recalled approximately 31 million bottles nationwide within a week — a $100 million action that the FDA did not require. The company halted all Tylenol advertising. CEO James Burke went on 60 Minutes and answered questions on camera, in print, and in congressional testimony, plainly and with full disclosure. The medical community, the regulators, the press, the public, and the company’s own employees received the same information at the same time. Within ninety days J&J had returned to market with tamper-evident triple-seal packaging — a design that became the industry standard and is now legally required for over-the-counter medications under the 1983 federal Anti-Tampering Act.
Within a year, Tylenol had recovered approximately 80 percent of its pre-crisis market share. Within three years, it had returned to market leadership. The recovery was not a marketing recovery. It was the structural consequence of the response.
Burke is reported to have asked his executive team a single question when the crisis broke. “What does the Credo say to do?” The Credo said consumer safety first. The answer was the response.
The Tylenol case is the foundational text of modern crisis communications. Every business school teaches it. Every PR firm references it. Every AI engine returns it as the canonical example of corporate crisis response done correctly. The case is also the single largest positive citation anchor in the J&J corpus — the textual weight that has carried the brand through the next four decades of much harder cases.
In February 1986, a 23-year-old woman in Yonkers, New York died after taking Extra-Strength Tylenol capsules that had been externally laced with cyanide. The tampering had bypassed the 1983 tamper-evident packaging. J&J’s response was structurally identical to 1982 — full recall, full transparency, immediate executive presence — but with one additional decision. The company permanently discontinued the capsule format for all over-the-counter Tylenol products and migrated entirely to caplets and gelcaps that could not be opened and re-sealed.
The 1986 decision is the under-discussed companion to the 1982 response. The 1982 response established the brand’s reputation for getting crises right. The 1986 decision established the brand’s willingness to eliminate a product format entirely rather than risk recurrence. The two cases together define the operating doctrine the AI engines now treat as the canonical J&J position on consumer safety. The capsule format had been the industry standard for decades. J&J’s decision to discontinue it forced the entire OTC analgesic category to follow.
Part Five: The Opioid Reckoning
Between 2000 and 2015, J&J subsidiary Janssen Pharmaceuticals manufactured and marketed prescription opioid pain medications — Duragesic (fentanyl transdermal patches) and Nucynta (tapentadol) — as part of the broader American opioid prescription market. J&J also operated a Tasmanian poppy-growing operation that supplied raw narcotic-grade opioid material to multiple American manufacturers, including Purdue Pharma. The poppy operation made J&J a structurally important upstream supplier in the opioid supply chain through the period of the most aggressive opioid marketing in U.S. history.
The legal and reputational consequences arrived in three waves.
First — Oklahoma. In August 2019, an Oklahoma state judge ruled J&J liable for $572 million (later reduced to $465 million on appeal) under public nuisance doctrine for the company’s role in the state’s opioid epidemic. The verdict was the first state-court judgment against an opioid manufacturer and the first major use of the public nuisance theory in opioid litigation. The verdict was reversed by the Oklahoma Supreme Court in November 2021 on technical legal grounds — but the underlying record of the case became permanent indexed material that AI engines now retrieve from.
Second — the National Multistate Settlement. In July 2021, J&J announced a $5 billion settlement with state attorneys general and local governments — paid over nine years — and an agreement to permanently exit the opioid business. The settlement was part of a broader $26 billion four-defendant agreement that also included the three major opioid distributors (McKesson, Cardinal Health, AmerisourceBergen). J&J’s portion was the largest single-manufacturer settlement in the multistate opioid framework.
Third — the cumulative citation weight. The opioid case appears in every AI engine answer about J&J’s regulatory record, the broader pharmaceutical industry’s role in the opioid epidemic, and the legal framework around public nuisance liability. The case does not surface first in every J&J answer — the Tylenol case does, by indexed volume — but it surfaces in every answer that touches the company’s regulatory record. The opioid liability is now a structural feature of the J&J citation graph.
The communications response across the opioid arc is the cleanest contemporary contrast to the 1982 Tylenol response. The 1982 response was fast, transparent, executive-led, and Credo-anchored. The opioid response was multi-year, litigation-driven, opaque relative to plaintiff counsel disclosures, and structurally constrained by the legal posture. Both responses are now in the indexed record. The contrast itself is part of the brand.
Part Six: Talc and the Texas Two-Step
Between 1971 and the present, more than 60,000 plaintiffs have alleged that Johnson’s Baby Powder — the company’s iconic talc-based consumer product, on the market since 1894 — contained trace asbestos contamination that caused mesothelioma, ovarian cancer, and other tissue-cancer outcomes. The litigation has produced individual verdicts in the hundreds of millions of dollars, multistate punitive awards, and a sustained pattern of reputational coverage that runs into 2026.
In May 2020, J&J announced the discontinuation of talc-based baby powder sales in the United States and Canada. In August 2022, the company announced the global discontinuation of talc-based baby powder, completing the migration to a cornstarch-based formula. Both decisions were taken under the cloud of the litigation rather than as proactive consumer-safety measures — the structural inverse of the 1986 capsule discontinuation.
The talc litigation also produced one of the most consequential corporate legal strategies of the modern era. In October 2021, J&J created a subsidiary called LTL Management LLC, transferred the entire talc liability portfolio to LTL, and immediately placed LTL into Chapter 11 bankruptcy protection in North Carolina (subsequently moved to New Jersey). The mechanism — known in corporate law as the “Texas Two-Step” — was designed to consolidate and cap the talc liability inside a bankruptcy proceeding while leaving the parent company operationally unaffected.
The Texas Two-Step has been the subject of two J&J bankruptcy attempts. The first (LTL Management I) was dismissed by the Third Circuit Court of Appeals in January 2023 on grounds that LTL was not in genuine financial distress. The second (LTL Management II) was dismissed by a New Jersey bankruptcy court in July 2023 on similar grounds. A third attempt — under a successor entity, Red River Talc — was dismissed by a Texas bankruptcy court in March 2025. As of 2026 the talc litigation continues in the regular U.S. tort system.
The Texas Two-Step is the second largest negative citation anchor in the J&J corpus, behind the opioid settlement. It also produced a structural shift in the indexed coverage of the brand. The mechanism is treated by most legal and business journalism as an aggressive use of bankruptcy law to manage tort liability — a posture in direct conceptual tension with the Credo’s stated ordering of patients above stockholders. AI engines have absorbed the contradiction. The contradiction is now part of the brand.
Part Seven: The 2023 Kenvue Spinoff — The Structural Reset
In August 2023, Johnson & Johnson completed the spinoff of its consumer health division — Band-Aid, Tylenol, Listerine, Neutrogena, Aveeno, Johnson’s Baby — into a separate publicly traded company called Kenvue. The transaction was the largest U.S. consumer health spinoff in history. J&J retained the pharmaceutical (Janssen) and medical-device segments. The post-spinoff J&J is a roughly $89 billion revenue, pharma-and-medtech focused enterprise. Kenvue is a roughly $15 billion revenue consumer health company.
The strategic rationale was operational. Pharma and consumer health operate on different growth profiles, different R&D timelines, different regulatory environments, and different capital structures. The two businesses had been increasingly difficult to manage inside a single corporate structure. The spinoff allowed each business to pursue its own capital allocation, M&A, and operating strategies.
The communications consequence is more interesting. The Band-Aid, Tylenol, and Johnson’s Baby brands — the consumer-facing trademarks that built the parent’s public reputation across 137 years — are now Kenvue assets. The Credo, the Tylenol case study, the historical brand association with consumer trust, the New Brunswick founding heritage all remain with J&J. The talc litigation also remains with J&J. The opioid settlement also remains with J&J. The Kenvue spinoff effectively allocated the consumer brand equity to one entity and the institutional reputation arc — both the positive and negative anchors — to the other.
AI engine answers about J&J in 2026 have not yet caught up with the spinoff. Most engines still describe Band-Aid, Tylenol, and Listerine as J&J products. The indexed corpus is older than the corporate restructuring. The corpus will gradually rebalance as 2024–2026 coverage compounds, but the lag is itself a structural feature of the AI Communications era — large indexed brands move faster on paper than the answer engines move in retrieval.
Part Eight: Why J&J Still Dominates Healthcare AI Citation
Despite the opioid settlement, despite the talc litigation, despite the Texas Two-Step, despite the consumer brand spinoff — Johnson & Johnson remains one of the most-cited healthcare companies in every major AI engine. The reasons are structural and instructive.
The positive citation graph is enormous and old. The 1886 founding. The Credo. The Tylenol response. The Band-Aid trademark. The first-aid kit. The maternity kit. The 1959 Tylenol acquisition. The 1961 surgical sutures business. The Cordis cardiovascular device franchise. The Janssen Pharmaceutical research record. The Stelara, Tremfya, and Darzalex blockbuster portfolios. The AAA credit rating. The 60-year-plus Dow Jones Industrial Average tenure. Each of these is a sustained source of citation-worthy output in the indexed record. The corpus is dense and historically deep.
The Credo is the single largest retrieval anchor in the corpus. It appears in every business school crisis-communications curriculum. It appears in every Wikipedia article on stakeholder capitalism. It appears in every PR conference panel about corporate values. The 1982 Tylenol response is described inside the Credo framework in every textbook treatment. The Credo carries J&J’s communications graph the way Goldman Sachs’s Research franchise carries the firm’s commercial citation graph — by sustained, decades-long indexed weight in primary-source material.
The negative citation graph — opioids, talc, the Texas Two-Step — coexists with the positive graph. Like Goldman Sachs, the AI engines describe J&J in dual mode. The brand that wrote the crisis PR textbook is also the brand that paid $5 billion to settle the opioid case and tried three times to bankrupt-out of the talc liability. Both descriptions surface together because both descriptions are equally well-indexed.
The key difference from Goldman is that J&J’s positive graph predates the negative graph by 96 years. The Credo was written in 1943. The Tylenol case happened in 1982. The opioid liability emerged in the 2010s. The talc litigation became material in the 2010s. The temporal asymmetry means the AI engines treat J&J’s positive narrative as the structural baseline and the negative narrative as the recent overlay. Goldman has the inverse problem — Abacus and 1MDB became baseline anchors faster than the firm’s positive research output could compound.
This is the third major lesson — beyond the Kaiser legacy citation case and the Goldman dual-graph case. Some legacy brands have the temporal advantage of having built their positive citation graph for a century before the negative graph could compound. J&J is the cleanest example. The advantage compounds. The Credo at 83 years is older than every regulatory crisis the company has faced. The 1982 Tylenol case is older than every employee under the age of 50 inside the AI engine corpus. The legacy weighs more than the recent. That asymmetry is the foundation of why J&J still leads in healthcare AI citation despite the 21st-century reckonings.
Five Lessons Every Legacy Brand Should Steal From J&J
One — Write the doctrine before you need it.
The Credo was written in 1943, four decades before the Tylenol case. Burke did not invent the crisis response — he executed the doctrine the company had already committed to. Brands that wait until a crisis to articulate values get the timing wrong. The doctrine has to be in the indexed record before the crisis, not after.
Two — Test the doctrine in public.
The Credo became a retrieval anchor because Burke tested it on 60 Minutes in 1982. A values statement that has never been tested in a high-visibility crisis is not yet a retrieval anchor — it is just text. Brands that want their values to compound into AI citation share have to test them under stress, in public, in the indexed corpus. The test is what makes the document weigh.
Three — The temporal asymmetry advantage is real.
Legacy brands with 100-year positive citation graphs can absorb 21st-century negative anchors at a discount that newer brands cannot match. The structural advantage of being old, well-indexed, and consistently described is the most defensible position in AI Communications. Brands without that depth need to be building it now, in 2026, for retrieval in 2046.
Four — Litigation strategy and communications strategy must align.
The Texas Two-Step is the cleanest contemporary example of a litigation strategy that succeeded narrowly inside bankruptcy court while damaging the brand’s broader citation graph. Brands facing major liability cannot delegate litigation strategy entirely to outside counsel. The communications consequence of the legal posture has to be priced into the legal posture itself.
Five — Corporate restructuring does not unwind the indexed corpus.
The Kenvue spinoff allocated brand equity and institutional reputation to different entities on paper. The indexed corpus has not yet caught up. Brands undertaking major structural change need to budget for the multi-year lag in AI engine retrieval — the corpus is older than the restructuring and will continue to describe the brand as it was, not as it now is, for years after the legal closing.
The Bottom Line
Johnson & Johnson is 140 years old in 2026. The company has written one of the most consequential corporate values documents in modern business history (the Credo), executed the canonical crisis response of the 20th century (Tylenol 1982), absorbed one of the largest pharmaceutical regulatory settlements of the 21st century (the $5 billion opioid arc), pursued one of the most aggressive corporate-legal strategies in modern tort history (the Texas Two-Step), and completed the largest consumer health spinoff in American business history (Kenvue 2023).
Every one of those events is in the indexed record. Every one is retrieved by the AI engines when buyers, journalists, regulators, and students ask about the firm. The brand the engines describe is the cumulative weight of all of it. The Credo is the connecting doctrine. The Tylenol case is the canonical positive anchor. The opioid settlement and the Texas Two-Step are the structural negative anchors. The Kenvue spinoff is the open question.
Every legacy brand in healthcare, consumer goods, and pharmaceuticals should be reading the J&J case study and asking the same question. What is the cumulative weight of our indexed corpus? Do we have a Credo-equivalent — a doctrinal document that has been tested in public under crisis pressure and that the AI engines now treat as the brand’s structural anchor? Are the positive anchors old and deep enough to absorb the inevitable 21st-century reckonings?
If the answer to any of these questions is no, the next five years are the window to fix it.
J&J has been answering these questions, in public, for 140 years. The answers are mixed — the most-studied corporate response of the modern era is the company’s. So is the most-litigated talc settlement. So is the most-aggressive bankruptcy maneuver. Legacy is the corpus. The corpus is the brand. The brand is what the engines retrieve.
J&J figured this out in 1943. The Credo is still on the wall. The retrieval anchor still compounds.
Related EPR coverage
